Molecular structure of Vemurafenib, CAS Number: 918504-65-1
Vemurafenib (CAS 918504-65-1)
See product citations (11)
Alternate Names:
Vemurafenib is also known as PLX 4032.
Application:
Vemurafenib is a novel and orally bioavailable ATP-competitive inhibitor of B-RAFV600E, potent and with an IC50 of 31 nM.
CAS Number:
918504-65-1
Purity:
≥99%
Molecular Weight:
489.92
Molecular Formula:
C23H18ClF2N3O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Vemurafenib is a potent and novel inhibitor targeting B-RAFV600E with an IC50 of 31 nM. Its efficacy has been demonstrated in vitro through the eradication of melanoma cells. Notably, Vemurafenib also exhibits inhibitory effects on wild type B-Raf kinases. When combined with Taxol, vinblastine, and oxaliplatin, Vemurafenib synergistically suppresses the proliferation of B-RafV600E transformed cancer cells. Additionally, Vemurafenib effectively suppresses the growth of tumors harboring the B-Raf V600E mutation. It belongs to the class of BRAF inhibitors and has proven effective in managing metastatic melanoma, as well as other cancers like colorectal and non-small cell lung cancer. By inhibiting the activity of the BRAF enzyme, which drives the growth and metastasis of cancer cells, Vemurafenib disrupts the cell cycle and induces apoptosis, resulting in cancer cell death. Its impact extends beyond BRAF enzyme inhibition, as it has demonstrated the ability to suppress the expression of several genes involved in cell cycle regulation and apoptosis.
Vemurafenib (CAS 918504-65-1) References
- Vemurafenib-associated pancreatitis: case report. | Muluneh, B., et al. 2013. Pharmacotherapy. 33: e43-4. PMID: 23436544
- Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage. | Kimeswenger, S., et al. 2019. Melanoma Res. 29: 134-144. PMID: 30802229
- Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells. | Wozniak, DJ., et al. 2019. Mol Cancer Ther. 18: 937-946. PMID: 30926642
- Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. | Donadieu, J., et al. 2019. J Clin Oncol. 37: 2857-2865. PMID: 31513482
- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. | Mazieres, J., et al. 2020. Ann Oncol. 31: 289-294. PMID: 31959346
- Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database. | Neha, R., et al. 2021. Curr Rev Clin Exp Pharmacol. 16: 168-173. PMID: 32598268
- Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. | Mandel, VD., et al. 2022. J Dermatolog Treat. 33: 1368-1375. PMID: 32875931
- Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia. | Chung, SY., et al. 2020. BMJ Case Rep. 13: PMID: 32928833
- Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen. | Goh, CJH., et al. 2021. G3 (Bethesda). 11: PMID: 33604667
- Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis. | Eder, SK., et al. 2022. Blood Adv. 6: 970-975. PMID: 34619771
- Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase. | Yamada, R. and Yanagita, M. 2021. Kidney Int. 100: 1158-1160. PMID: 34802553
- Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming. | Chang, MT., et al. 2022. Pharmacol Res. 178: 106148. PMID: 35231572
- 3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. | Vital, PDS., et al. 2022. Int J Mol Sci. 23: PMID: 36555289
- Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. | Liu, Y., et al. 2022. J Pharm Pharm Sci. 25: 377-390. PMID: 36608646
Inhibitor of:
α-protein kinase 3, 2700089E24Rik, 4.1N, 9330182O14Rik, ABC1, AKIP, BAGE5, BBS8, BIGM103, BinCARD, Brk, C20orf160, C21orf77, cGKI, CNKSR3, CSAGE, DABP, DAN, DNHL1, DOCK 10, DOCK 5, Dokl, DSN1, ENT1, FAM149B1, Fis1, FLJ34931_BC027072, FLJ39531, GAGE3, gankyrin, GGH, Gm128, Gm3336, Gm9766, gp100, GRASP, Hairy Cell Leukemia Marker, Hck, HIP14L, HOOK2, HPK1, INSM2, Int-6, Kazrin, KIAA1549, Lefty, LGALS9, LOC440330, LOC645851, LOC728861, LOC729103, LOC729521, LOC730210, LPLUNC4, LZK, LZTR1, MAGE-6, MAGE-C3, MEK kinase-4, Melan-A, Melanoma Marker, MFRP, MGA, Mos, Mpk1, MTERF, N-Shc, NUCKS, NURIM, Olr1052, Olr1060, Olr1061, Olr1111, Olr1156, Olr1203, Olr1257, Olr130, Olr1384, Olr1404, Olr157, Olr165, Olr1739, Olr214, Olr367, Olr382, Olr482, Olr516, Olr665, Olr712, Olr734, Olr766, Olr775, Olr785, Olr791, Olr920, Olr996, OTTMUSG00000010673, OTTMUSG00000019784, PAGE-1, PAGE-5, PCDHGC, PCPTP1, Pet117, PHIP, PRAMEF12, PRIC285, PXDNL, Raf, Raf-1, raf-A, Raf-B, RAP1GDS1, RASAL2, Rat Tumor Marker, RBKS, RGL1, Rhox3, RIM-BP3B, RIT (Ras-like without CAAX), RREB1, Rslcan-11, RSPRY1, RSRC2, SB144, SCFD1, Ser/Thr Protein Kinase, Six5, SLURP-2, SNFT, Sp2, Sp3, SPPase1, SPRED1, SS18L2, ST7L, T3JAM, TESSP1, TFIIH p62, TFIP11, TRAAK, TRAP220, Trav12d-1, UMPS, V1RE8, Vmn1r191, WFIKKN2, YadA, and Zfp804b.Activator of:
BJ-TSA-9, CNK1, KIAA0649, Melanoma, MFAP3L, MITF, PRAME_Prame, raf-A, and SPRED1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vemurafenib, 10 mg | sc-364643 | 10 mg | $117.00 | |||
Vemurafenib, 50 mg | sc-364643A | 50 mg | $423.00 |